GOT1 and Hepatic steatosis: Six patients in the high-dose group reported events, mainly hepatic steatosis and abnormality in hepatic enzymes levels such as aspartate aminotransferase (AST), aspartate alanine transferase (ALT) elevations, but none of abnormalities based on the central laboratory exceeded >3 times upper limit of normal (ULN) range.